News

from Carrington Laboratories, Inc.


For Immediate Release
November 21, 1996

For Information Contact:
Jim Blackmore, APR
(972) 714-5046 or (800) 471-8817

CARRINGTON LABORATORIES INTRODUCES DIABETIC PRODUCT LINE

IRVING, TEXAS (11/21)--Carrington Laboratories (NASDAQ: CARN) is pleased to introduce its DiaB™ line of products formulated for individuals who suffer from diabetes. The DiaB™ line consists of four products:

DiaB™Nutri is a dietary supplement in tablet form.

DiaB™Klenz is a spray wound cleanser for diabetic leg and foot ulcers.

DiaB™Gel is a hydrogel wound care preparation for the management of diabetic ulcers.

DiaB™Cream is a routine, post-healing moisturizer cream.

In support of the launch of the DiaB™ product line, announcements have been placed in six professional journals, four medical marketing publications and one consumer journal. Targeted were those with the greatest need to know about the DiaB™product line including podiatrists, physicians, nurses, physical therapists, diabetic educators and diabetic consumers. Currently, there are eight million diagnosed diabetics in the United States.

Approximately 1.2 million diabetics suffer with lower extremity ulcers. Carrington's products were developed for this market segment. Carrington plans for its products to find a market for the management of diabetic ulcers and as a post amputation management tool. The DiaB™ line is marketed under an FDA 510K authorization to market. The company believes its DiaB™ product line contains the first hydrogel product specifically for the diabetic marketplace.

Diabetic ulcers are responsible for approximately 60,000 limb amputations each year. The average cost for each primary amputation is $40,563. This represents a $2.4 billion annual cost to the American healthcare system.

A company spokesman said, "Carrington's Carrasyn®; Hydrogel Wound Dressing was the first on the market and is the current market leader. We expect the DiaB™ Gel and support products to be well received in this segment of the wound care market."

Some of the above statements about Carrington's plans for the DiaB™ line are forward-looking. Size of the diabetic market is based on outside sources and may vary. Factors which may bear on these statements include but are not limited to the following: subsequent changes in plans by the company's management; developments in the treatment protocols; acceptance of products; third party licensing; changes in industry trends; actions of the company's competitors; changes in the aging population base; and, a number of other factors and risks described from time to time in the company's reports filed with the Securities & Exchange Commission, including the Form 10-Q for the quarter ended September 30, 1996.

Carrington Laboratories, Inc., is an emerging research-based pharmaceutical and medical device company engaged in developing complex carbohydrate-based therapeutics and oral technology products, and in manufacturing and marketing products for the management of wounds. Carrington currently has over 50 products on the market.

Carrington Laboratories Inc
2001 Walnut Hill Lane
Irving, Texas 75038
Tel:(972) 518-1300
Fax: (972) 518-1020